Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis.
SGLT2 inhibitor
contrast-induced AKI
coronary artery disease
diabetes mellitus
percutaneous coronary intervention
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
19
05
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
Contrast-induced acute kidney injury (CI-AKI) is a common complication of patients undergoing percutaneous coronary intervention (PCI). Data regarding the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitor on the CI-AKI incidence and renal outcomes of patients undergoing PCI are limited. This study aimed to examine the real-world risk of CI-AKI in SGLT2 inhibitor users undergoing PCI. We used longitudinal data from the medical records of the First Affiliated Hospital of Xi'an Jiaotong University. We selected SGLT inhibitor users and nonusers [patients with type 2 diabetes (T2D) without SGLT2 inhibitor prescription] undergoing PCI. We determined CI-AKI by the ESUR (European Society of Urogenital Radiology, AKI We identified 242 SGLT2 inhibitor users and 242 nonusers in the cohort. The unadjusted ORs of CI-AKI Our findings do not suggest an increased risk of CI-AKI associated with SGLT2 inhibitor use in patients with CAD and T2D undergoing PCI.
Sections du résumé
Background
UNASSIGNED
Contrast-induced acute kidney injury (CI-AKI) is a common complication of patients undergoing percutaneous coronary intervention (PCI). Data regarding the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitor on the CI-AKI incidence and renal outcomes of patients undergoing PCI are limited. This study aimed to examine the real-world risk of CI-AKI in SGLT2 inhibitor users undergoing PCI.
Methods
UNASSIGNED
We used longitudinal data from the medical records of the First Affiliated Hospital of Xi'an Jiaotong University. We selected SGLT inhibitor users and nonusers [patients with type 2 diabetes (T2D) without SGLT2 inhibitor prescription] undergoing PCI. We determined CI-AKI by the ESUR (European Society of Urogenital Radiology, AKI
Results
UNASSIGNED
We identified 242 SGLT2 inhibitor users and 242 nonusers in the cohort. The unadjusted ORs of CI-AKI
Conclusion
UNASSIGNED
Our findings do not suggest an increased risk of CI-AKI associated with SGLT2 inhibitor use in patients with CAD and T2D undergoing PCI.
Identifiants
pubmed: 35795364
doi: 10.3389/fcvm.2022.918167
pmc: PMC9251334
doi:
Types de publication
Journal Article
Langues
eng
Pagination
918167Informations de copyright
Copyright © 2022 Hua, Ding, Guo, Wu, Yuan and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9
pubmed: 15464318
Circulation. 2011 Feb 1;123(4):409-16
pubmed: 21242477
Kidney Med. 2021 Jun 26;3(4):674-675
pubmed: 34401735
Dis Markers. 2021 Dec 18;2021:8959019
pubmed: 34961824
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Care. 2018 Aug;41(8):1543-1556
pubmed: 30030256
Am J Kidney Dis. 2022 Jun;79(6):858-867.e1
pubmed: 34762974
J Am Soc Nephrol. 2014 Feb;25(2):216-24
pubmed: 24309187
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Nat Rev Nephrol. 2016 Nov 16;12(12):711-712
pubmed: 27847389
Cardiovasc Diabetol. 2022 Feb 5;21(1):20
pubmed: 35123480
Diabetes Care. 2017 Nov;40(11):1479-1485
pubmed: 28827404
J Am Coll Cardiol. 2018 Jun 26;71(25):2880-2889
pubmed: 29929610
Cardiovasc Drugs Ther. 2016 Apr;30(2):215-28
pubmed: 26780748
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617
pubmed: 31196815
Eur J Heart Fail. 2022 Mar;24(3):431-441
pubmed: 34894038
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110
pubmed: 31862752
N Engl J Med. 2020 Apr 9;382(15):1395-1407
pubmed: 32227755
Kidney Med. 2021 Jan 07;3(2):282-285
pubmed: 33851124
Diabetes. 2020 Nov;69(11):2229-2237
pubmed: 33082271
Circulation. 2019 Nov 19;140(21):1693-1702
pubmed: 31434508
Front Pharmacol. 2021 Dec 21;12:781379
pubmed: 34992535
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285